Randomized Evaluation of D-dimer Guiding dUration of Oral antiCoagulation thErapy
Status:
Unknown status
Trial end date:
2021-03-30
Target enrollment:
Participant gender:
Summary
Guidelines recommended that patients with bioprosthetic heart valves (BHV) only need 6 months
oral anticoagulation therapy after operation. However, a small part of patients still
suffered thrombotic events after withdrawal of warfarin, which means these patients may need
extend anticoagulation therapy. D-dimer, a sensitive marker of thrombosis or
prethromboembolism state. Previous studies have demostrated that patients with elevated
D-dimer levels have significant more clinical outcomes than those with nagative D-dimer
levels. The aim of this study was to evaluate whether D-dimer could guide the duration of
oral anticoagulation therapy in patients with BHV.